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Introduction
Worldwide, breast cancer is the most common cancer
in women, excluding skin cancers [1], with a lifetime risk
of 10% in the general population [2]. In spite of earlier
detection and better treatment, largely due to recent
technological advances, it is still the second leading
cause of cancer death in women, exceeded only by lung
cancer [3]. The three commonest cancers, excluding
skin cancer, in the Iranian population (females, all ages),
are cancers of the oesophagus, breast and cervix, in
diminishing order of incidence [4]. A preliminary study
showed no significant differences in age-specific
PTT = protein truncation test; SSCP = single-strand conformation polymorphism.
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Abstract
Background: Breast cancer is the most common female malignancy and a major cause of death in
middle-aged women. So far, germline mutations in the BRCA1 and BRCA2 genes in patients with
early-onset breast and/or ovarian cancer have not been identified within the Iranian population.
Methods: With the collaboration of two main centres for cancer in Iran, we obtained clinical
information, family history and peripheral blood from 83 women under the age of 45 with early-onset
breast cancer for scanning of germline mutations in the BRCA1 and BRCA2 genes. We analysed
BRCA1 exons 11 and BRCA2 exons 10 and 11 by the protein truncation test, and BRCA1 exons 2,
3, 5, 13 and 20 and BRCA2 exons 9, 17, 18 and 23 with the single-strand conformation
polymorphism assay on genomic DNA amplified by polymerase chain reaction.
Results: Ten sequence variants were identified: five frameshifts (putative mutations — four novel); three
missense changes of unknown significance and two polymorphisms, one seen commonly in both
Iranian and British populations.
Conclusions: Identification of these novel mutations suggests that any given population should
develop a mutation database for its programme of breast cancer screening. The pattern of mutations
seen in the BRCA genes seems not to differ from other populations studied. Early-onset breast cancer
(less than 45 years) and a limited family history is sufficient to justify mutation screening with a
detection rate of over 25% in this group, whereas sporadic early-onset breast cancer (detection rate
less than 5%) is unlikely to be cost-effective.
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incidences among Iranian women with breast cancer, in
comparison with other studies [5,6].
Hereditary breast cancer is suspected in an individual who
has a family history of breast cancer, or breast and ovarian
cancer, that is consistent with autosomal dominant inheri-
tance [7]. Many efforts are now under way to reduce the
high incidence and mortality associated with breast and
ovarian cancer by the early detection of women at high
risk. These women, once identified, can be targeted for
more aggressive prevention programs. Breast cancer is
not a systemic disease at its inception but is progressive;
screening can arrest its development and the treatment of
advanced breast cancer is often futile and disfiguring [8].
In 1990, the first breast cancer susceptibility gene,
BRCA1, was localised by linkage analysis to chromosome
17q21 [9]. Miki et al. [10] isolated the BRCA1 gene in
1994. Subsequently, Wooster et al. [11] identified a new
gene,  BRCA2. Both BRCA1 and  BRCA2 are large
genes, consisting of 24 and 27 exons, respectively. Muta-
tions in BRCA genes are distributed throughout the
coding region. Women who carry BRCA1 and BRCA2
mutations have a significantly increased chance of devel-
oping breast cancer before the age of 50 years [12–14].
Some studies indicate that 13% of women who are diag-
nosed with breast cancer under the age of 30 years, and
7% of women who are diagnosed with breast cancer
under the age of 35 years, have germline BRCA1 alter-
ations [12,15]. No molecular genetics study of BRCA1
and BRCA2 germline mutations has been reported in the
Iranian population and there are few individuals with
strong family histories that have as yet been identified. We
therefore selected women who were most likely to harbour
germline mutations in these genes.
Mutational spectrum
At present, over 878 distinct mutations, polymorphisms
and variants throughout the BRCA1 gene have been dis-
covered [16]. Over 900 distinct alterations have been
identified in BRCA2 [16] and, as in BRCA1, they are not
limited to a particular region of the gene. Most mutations
in both genes are private [16]. BRCA1 is considered to
be responsible for about one-half of all cases of early-
onset breast cancer and for the majority of familial breast
and ovarian cancers [9,17]. BRCA1 somatic mutations
have never been reported in sporadic breast cancer [18]
although they have occasionally been found in sporadic
ovarian cancers [19,20].
Materials and methods
Design
We performed the present study to obtain initial experi-
ence in identifying germline mutations in the BRCA1 and
BRCA2 genes in Iranian women diagnosed with early-
onset breast cancer.
With the cooperation of two main centres for cancer
research and treatment in Tehran, Iran, namely the Iranian
Centre for Breast Cancer and the Cancer Institute at
Tehran University of Medical Sciences, 83 samples derived
from 82 unrelated Iranian families were selected for screen-
ing of germline mutations in BRCA1 and BRCA2.
During 3 years since 1997, the medical records of 152
women diagnosed with breast cancer at the Iranian
Centre for Breast Cancer were reviewed and 39 patients
were selected for screening. In the 12 months after
December 1999, a consecutive series of 44 patients from
the Cancer Institute who were diagnosed with breast
cancer were chosen for screening. All selected patients
from these two centres were under the age of 45 years.
All selected women were informed that their DNA samples
would be analysed for known mutations in genes associated
with susceptibility to breast cancer; they were offered the
opportunity to receive the results and were asked to sign a
second consent form if they chose to learn the results.
DNA isolation and mutation analysis
Using a Promega DNA purification kit (catalogue no.
LA1620) and in accordance with the manufacturer’s pro-
tocols, genomic DNA was extracted from peripheral blood
lymphocytes at the Pasteur Institute in Tehran, Iran.
We analysed BRCA1 exon 11 and BRCA2 exons 10 and
11 by the protein truncation test (PTT) [21–23], and
BRCA1 exons 2, 3, 5, 13 and 20 and BRCA2 exons 9,
17, 18 and 23 by the single-strand conformation polymor-
phism (SSCP) assay [24] and heteroduplex analysis [25]
by amplification from genomic DNA with the polymerase
chain reaction (PCR).
Although mutations are scattered throughout both BRCA1
and BRCA2, some coding regions were particularly chosen
for several reasons: first, it has been shown that they have a
significant role in protein function (exons 2–5, Ring finger
domain [26]; exon 11 and exon 20, BRCT domain) [27];
second, exons 10 and 11 cover a large segment of the
gene; third, many putative mutations have been reported in
these regions; and fourth, the coding regions listed above
have been shown in other significant studies [28–32] to be
most likely to harbour germline BRCA1 and BRCA2 muta-
tions. A comparison of data from other studies suggests
that, with this strategy, about 14% and 22% of mutations in
BRCA1 and  BRCA2, respectively, would be missed.
However, there are no data to indicate the presence of pop-
ulation-specific mutations in Iran; these data must therefore
be considered preliminary [28–32].
The PTT method
Most mutations reported in BRCA1 and BRCA2 cause
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detectable by PTT; PTT is a very sensitive and efficient
tool for mutation detection [28].
Modified primers containing a T7 promoter and a perfect
Kozak consensus sequence were used to generate PCR
products of the whole of exon 11 of BRCA1 and exons 10
and 11 of BRCA2 that were suitable for PTT. Each primer
pair amplified 3446 base pairs (bp) and 4959 bp for
BRCA1 exon 11 and BRCA2 exon 11, respectively.
Regions (the 5′ and 3′ ends) of exon 11 in both genes
were screened separately to identify any potential
decrease in the sensivity of PTT resulting from the use of
such large fragments.
PCR programme
PCRs were performed with genomic DNA containing
50 ng of genomic DNA, 1 µl of each primer at 5 pmol/µl,
2 µl of a mixture of dNTPs (each at 2.5 mM), 2.5 µl of
5 × PCR buffer A [300 mM Tris-SO4 (pH 9.1 at 25°C),
90 mM (NH4)2SO4 and 5 mM MgSO4] and 2.5 µl of buffer
B [300 mM Tris-SO4 (pH 9.1 at 25°C), 90 mM
(NH4)2SO4 and 10 mM MgSO4], 1 µl of Elongase®
Enzyme Mix (Invitrogen, Paisley, UK) in accordance with
manufacturer’s recommendations, and distilled water was
added to a final volume of 25 µl. For amplification, each
sample was denatured at 94°C for 1 min and subjected to
31 cycles of PCR (94°C for 25 s, 56°C for 1 min, and
extension at 68°C for 4 min on an Applied Biosystems
DNA thermal cycler, Applera Europe BV, Cheshire, UK);
this was followed by incubation at 68°C for 10 min. The
PCR products were checked on a 0.7% agarose gel and
a 1 µl sample was used for a coupled transcription–trans-
lation reaction (TNT® T7 Quick for PCR DNA kit from
Promega, Southampton, UK; catalogue no. L5540), in
accordance with the instructions of the manufacturer. Full-
length artificial proteins of BRCA1 and BRCA2 exon 11,
126 and 182 kDa, respectively, labelled with 35S, were
detected after SDS-PAGE [33] (see Fig. 2) on a 2 × Mini-
Protean system (Bio-Rad, Hertfordshire, UK, catalogue no.
165-3301).
The SSCP assay
BRCA1 exons 2, 3, 5, 13 and 20, BRCA2 exons 9, 17,
18 and 23 and the 5′ and 3′ ends of exon 11 of BRCA1
and BRCA2 were analysed with the SSCP method.
PCR was performed on 50 ng of genomic DNA, 1 µl of
5 pmol/µl forward primer, 1 µl of 5 pmol/µl reverse primer,
1.6 µl of a mixture of dNTPs (each at 2.5 mM), 2 µl of
10 × PCR reaction buffer [750 mM Tris-HCl (pH 8.8 at
25°C), 200 mM (NH4)2SO4 and 0.1% (v/v) Tween 20],
0.7 unit of Red Hot Taq DNA polymerase, made up to a
final volume of 20 µl with distilled water. For amplification,
each sample was denatured at 94°C for 2 min and sub-
jected to 28–30 cycles of PCR (at 94°C for 30 s, at
55–60°C for 1 min, and extension at 74°C for 1 min on a
Perkin-Elmer-Cetus DNA thermal cycler); this was fol-
lowed by incubation at 72°C for 5 min. Annealing temper-
atures varied according to the melting temperature, Tm, of
the primer template.
SSCP analysis for point mutations was performed under
the following conditions: a mixture of 5 µl of a 28-cycle
PCR product and 5 µl of loading buffer was denatured for
10 min at 95°C, cooled rapidly on ice and separated on a
non-denaturing 14% polyacrylamide gel (57:1 acry-
lamide:bisacrylamide, 3–10% glycerol) in 0.5 × Tris-
borate-EDTA buffer at 12–16°C for 16–20 h at 245 V.
Bands were revealed by silver staining.
Direct sequencing
All sequence variants were confirmed by using the PCR
products of each sequence variant and Big Dye dideoxy-
terminator chemistry (Perkin-Elmer) on an ABI 377 DNA
sequencer (Applied Biosystems).
Primer design
For SSCP, splice junctions were included in the analysis
in all cases. In addition, four sets of primers were used to
screen the 5′ and 3′ ends of exon 11 of BRCA1 and
BRCA2. For PTT, two sets of primers were designed to
screen the whole of exon 11 of BRCA1 and BRCA2.
Results
We have identified ten sequence variants in this cohort:
five frameshifts, four of which were novel (Figs 1 and 2),
three missense changes of unknown significance and two
polymorphisms.
A common polymorphism in BRCA2 [IVS16-14T>C] was
identified in both Iranian and British populations. No
sequence variant was detected at the 5′ and 3′ ends of
exon 11 in BRCA1 and BRCA2 by SSCP analysis, sug-
gesting that there was no loss of sensitivity in analysing
such large fragments by PTT.
Tables 1 and 2 describe the distribution of BRCA1 and
BRCA2 mutations respectively by the type of mutations.
Discussion
This is the first report to describe mutations in the BRCA
genes in the Iranian population. The cohort studied all had
early-onset (less than 45 years) breast cancer; a subgroup
had a family history that was quite limited (Tables 1 and 2)
in comparison with most other studies [34–37]. These
preliminary data suggest that the spectrum of mutations
identified differs little from that seen in other studies, with
no recurrent mutation and the mutations spread through-
out the genes. Five putative (frameshift) mutations were
detected in the group as a whole (6.02% detection rate)
in which four mutations were detected among 14 individu-
als with a family history (28.6% detection rate with 95%
Available online http://breast-cancer-research.com/content/4/4/R6binomial confidence interval 0.09–0.58), whereas one
mutation was seen in a patient among 69 individuals with
early onset breast cancer but without a family history
(1.5% detection rate with 95% binomial confidence inter-
val 0–0.09) [38].
In many of the study cohort, we failed to identify a causative
mutation, regardless of the presence or absence of a family
history and these may simply be sporadic cases. However,
it is clear that the known genes cannot explain most of the
variation in breast cancer risk in the population. The difficul-
ties of identifying further genes by linkage indicate that the
remaining genes might be numerous, with relatively
common alleles conferring moderate risks. Only by identify-
ing these genes will the true pattern of risk and the mecha-
nism behind them become clear [39].
Conclusions
The detection rate in those with a family history was high,
especially when compared with other studies in which the
selection criteria for screening required a much stronger
family history. This suggests that the screening, albeit
incomplete, was well targeted. The low detection rate in
those with apparently sporadic early-onset cancer sug-
gests that early-onset cancer alone is insufficient to justify
screening in the Iranian population. If these results were
confirmed on a large cohort, molecular methods would
form a vital part of any screening programme in Iran.
GenBank accession numbers
These sequence variants have already been submitted to
GenBank: accession numbers AF274503, AF284812,
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Figure 1
Single-strand conformation polymorphism (SSCP) assay for germline
mutation in BRCA1 exon 2. Lanes 1 and 4 show normal patterns, and
lane 2 and 3 depict the abnormal patterns of single-strand DNA
mobility seen on a polyacrylamide gel (b). Frameshift mutation in
sample (lane 2) confirmed by direct sequencing (a) that shows a 2 bp
(AG) deletion in BRCA1 exon 2 at nucleotides 185–186 that leads to
the formation of TGA at codon 39. (c) A frameshift mutation (lane 3)
identified by direct sequencing, which revealed a 1 bp (T) insertion in
BRCA1 exon 2 between nucleotides 181 and 182, leading to the
formation of TGA at codon 40. These frameshift mutations are likely to
disrupt the function of the BRCA1 proteins.
Figure 2
SDS-PAGE analysis of the whole of exon 11 of BRCA2, revealing the
capacity of the PTT technique to detect mutations within 4959 bp
coding sequences in a single reaction with the use of a coupled
transcription–translation system, TNT® T7 Quick for PCR DNA kit from
Promega. Lanes 1 and 2 show the normal pattern of the full-length
(181 kDa) protein from exon 11 of BRCA2; lanes 3–5 show three
different sizes of truncated protein, which were identified on 6% SDS-
PAGE. Arrows show the sizes and positions of the normal and
truncated proteins. Lane 4 shows a mutation occurring close to the 3′
end of exon 11 and producing a large protein for which the band
migrated close to the top of the gel.AF288936, AF288937, AF288938, AF309413, AF317283,
AF348515, AY008850 and AY008851.
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